Methods, apparatuses, and systems for continuously inactivating a virus during manufacture of a biological product

Patent metadata

Field	Value
Publication number	US-11725191-B2
Application number	US-201916549203-A
Country	US
Kind code	B2
Filing date	Aug 23, 2019
Priority date	Apr 15, 2014
Publication date	Aug 15, 2023
Grant date	Aug 15, 2023

Abstract

Methods for continuously inactivating virus during manufacture of a biological product are provided. The methods include steps of (1) combining (a) a composition including a biological product, and (b) a composition including a virus-inactivation reagent, to obtain (c) a treatment composition having a predetermined property for inactivation of a virus, (2) confirming that the treatment composition exhibits the predetermined property, (3) transferring the treatment composition to a treatment vessel that includes an inlet, an outlet, and a static mixer, the transferring occurring at the inlet, (4) incubating the treatment composition in the treatment vessel at a predetermined temperature while the treatment composition flows at a predetermined rate and contacts the static mixer, and (5) collecting the treatment composition from the treatment vessel at the outlet, wherein steps (1) to (5) are carried out continuously. Apparatuses and systems including such a treatment vessel are also provided.

First claim

The invention claimed is:

1. An apparatus for continuously inactivating a virus during manufacture of a biological product, the apparatus comprising:
an initial-mixing vessel;
a pre-treatment detector chamber, wherein the pre-treatment detector chamber is not a chromatography column;
a pre-treatment hold reservoir;
a drain valve; and
a treatment vessel that comprises an inlet, an outlet, and a static mixer, the inlet and the outlet being positioned at opposite ends of a major axis of the treatment vessel and the static mixer being internal to the treatment vessel along the major axis;
wherein:
the initial-mixing vessel, the pre-treatment detector chamber, the pre-treatment hold reservoir, and the treatment vessel each have an internal volume and are fluidically connected in series;
the drain valve is either connected to, and positioned between, the pre-treatment hold reservoir and the inlet of the treatment vessel, or connected to the outlet of the treatment vessel; and
the ratio of the internal volume of the pre-treatment hold reservoir to the internal volume of the treatment vessel is 0.003 to 0.06.

2. The apparatus of claim 1 , wherein:
the internal volume of the pre-treatment hold reservoir is 25 mL to 14 L; and
the internal volume of the treatment vessel is 8 L to 250 L.

3. The apparatus of claim 1 , wherein:
the internal volume of the pre-treatment hold reservoir is 0.63 mL to 1.4 L; and
the internal volume of the treatment vessel is 200 mL to 25 L.

4. A system for continuously inactivating a virus during manufacture of a biological product, the system comprising:
a perfusion bioreactor; and
the apparatus of claim 1 ;
wherein:
the perfusion bioreactor and the apparatus are connected via the initial-mixing vessel; and
the perfusion bioreactor has an internal volume that is 5 to 2400 fold greater than the internal volume of the treatment vessel.

Assignees

• Boehringer Ingelheim Int

Inventors

• Coffman jonathan
• Goby Jeff
• Godfrey Scott
• Orozco Raquel
• Vogel Jens Holger

Classifications

• A61L2/16

  using chemical substances · CPC title

• A61L2103/05

  Living organisms or biological materials · CPC title

• A61L2/18 Primary

  Liquid substances · CPC title

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61L2/0082

  Human Necessities · mapped topic